Disc Medicine GAAP EPS of -$1.53 beats by $0.20 (IRON:NASDAQ)
Disc Medicine reported Q3 GAAP EPS of -$1.53, beating estimates by $0.20. The company had $683M in cash and equivalents, and raised $486M in a public offering in October 2026, extending its cash runway.
How this was made
The 30-second read
Why it matters
The earnings beat and cash runway provide a catalyst for short‑term price movement.
Market read
First‑report earnings beat for a micro‑cap biotech, offering actionable insight for traders.
What to watch
Potential dilution from the recent $486M offering could offset cash benefits.
Background
Disc Medicine (NASDAQ: IRON) issued a press release announcing its Q3 results and cash position.
Ticker impact
Disc Medicine reported Q3 GAAP EPS of -$1.53, beating expectations by $0.20, and disclosed $683M cash and a $486M capital raise.
likely upward pressure as the market prices in the earnings beat and cash runway.
The beat and sizable cash reserve are fresh information that can move the stock in after‑hours trading.
Market effects
The biotech sector may see modest uplift as a peer demonstrates strong cash generation.
US small‑cap biotech investors could re‑allocate toward Disc Medicine.
Limited to investors tracking US biotech earnings.
Counterpoint
The negative EPS and ongoing losses may still weigh on the stock despite the beat.
Key entities
- CompanyDisc Medicine
Biotech firm listed on NASDAQ under ticker IRON.